Evidence map›Paper›PMID 41080547›Full record

ArticleFrontiers in immunology2025

Clinical, immunological, molecular characteristics and outcomes of stem cell transplantation in

Fai AlQahtani, Azhar Al Shaqaq, Bandar Al-Saud, Nora AlRumayyan, Reem Mohammed, Rand Arnaout, Sahar Elshorbagi, Sultan Albuhairi, Ali Al-Ahmari, Mouhab Ayas and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fai AlQahtaniDepartment of Pediatrics, Collage of Medicine, King Fahad Hospital of the University, Alkhobar, Saudi Arabia.
Azhar Al ShaqaqDepartment of Pediatrics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Bandar Al-SaudDepartment of Pediatrics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Nora AlRumayyanDepartment of Pediatrics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Reem MohammedDepartment of Pediatrics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Rand ArnaoutDepartment of Pediatrics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Sahar ElshorbagiDepartment of Pediatrics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Sultan AlbuhairiDepartment of Pediatrics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Ali Al-AhmariDepartment of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Mouhab AyasDepartment of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Hawazen Al-SaediDepartment of Pediatric Hematology/Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Abbas HawwariDepartment of Translational Genomics, Genomic Medicine Centre of Excellence, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Anas M AlazamiDepartment of Translational Genomics, Genomic Medicine Centre of Excellence, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Hamoud Al-MousaDepartment of Pediatrics, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Zeta-chain-associated protein kinase 70 ( Methods: We retrospectively reviewed all patients with genetically confirmed Results: Thirteen patients with a median age at symptom onset of 1 month were identified. The most frequent initial presentations were recurrent respiratory infections and cutaneous manifestations. Autoimmune complications and lymphoproliferation were observed in several patients. Eleven of thirteen patients (84.6%) exhibited profound CD8 Conclusion: HSCT remains the only curative treatment for

Indexed as

Hematopoietic Stem Cell TransplantationPrimary Immunodeficiency DiseasesZAP-70 Protein-Tyrosine KinaseChild, PreschoolFemaleGraft vs Host DiseaseHumansInfantMaleRetrospective StudiesSevere Combined ImmunodeficiencyTreatment OutcomeZAP70 protein, humanZAP-70 Protein-Tyrosine KinaseCD8 deficiencyhematopoietic stem cell transplantimmunodeficiencyinborn error of immunitySCIDsevere combined immunodeficiency diseaseZAP-70 deficiency

Identifiers

PMID41080547
PMCPMC12507918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.